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Corticosteroids are a class of potent drugs with important physiological effects on the body. Regular use is linked with 
common and serious side effects. This paper uses studies to analyze the similarities between various corticosteroids. All 
drugs in this class are molecules that contain the same steroid backbone and are therefore associated with the same 
cellular receptor. This results in a comparable mechanism and parallel overall effect in the body. Side effects of cortico-
steroids are analogous as well. Using the knowledge of physiological changes in the body due to corticosteroids will al-
low healthcare providers to determine the most effective corticosteroid least likely to cause adverse effects, and treat 
and monitor the patient accordingly.  
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Introduction 
 Corticosteroids are a class of commonly prescribed 
drugs containing a backbone of four fused cycloalkanes. 
These drugs are prescribed to treat a wide variety of ail-
ments including: autoimmune disorders, arthritis, asthma, 
dermatitis, cancer treatment, pain management and oth-
ers. Corticosteroid drug therapy is currently used in the 
treatment of over 175 diseases. Additionally, these drugs 
are commonly used by patients, as seen by the fact that 
Advair diskus, a corticosteroid inhaler, was sixth in retail 
sales during the year 2013. The drug can be administered 
and absorbed by the body in a variety of different forms: 
topically applied creams, inhaled sprays, injected systemi-
cally, drops for the eyes or ears, and orally. What are the 
common physiological effects of the different corticoster-
oids? The medications in this class share a common molec-
ular backbone and cause analogous effects on a cellular 
level. Much research has been done trying to determine an 
exact mechanism of steroidal function. Mechanisms have 
been proposed, but as of today, they are hypotheses that 
explain some, but not all, effects. Though corticosteroid 
drugs are used for seemingly disparate pathologies, there 
are many similarities in physiological effects of corticoster-
oids, both medicinal as well as detrimental. 
Methods 
The similarities between the corticosteroid class of drugs, 
as well as the differences between specific corticosteroids, 
were analyzed using original studies and critiques obtained 
by typing corticosteroid along with other associated key-
words, such as inflammation, into databases, such as  
Ebsco, Medline, ProQuest, and other similar databases. 
Similarity in Structure 
 Steroids are molecules with a backbone consisting 
of three bonded cyclohexane rings fused with a cyclopen-
tane. The backbone can vary in oxidation state as well as in 
functional groups, producing numerous different steroid 
molecules. The body produces cholesterol and steroid hor-
mones as part of normal function, most importantly: aldos-
terone, and the sex hormones. Synthetic steroids can be 
introduced into the body. 
 Corticosteroids are a class of drugs similar to the 
hormone cortisol, and they contain this steroid backbone. 
Different corticosteroids vary somewhat in shape due to 
the differing functional groups and oxidation state. Though 
all steroid molecules are quite similar in structure, slight 
changes between each molecule’s backbone results in 
differing affinity between the molecule and the corre-
sponding glucocorticoid receptor . Structural changes also 
affect the bioavailability of a corticosteroid. Inhaled corti-
costeroids with a hydroxyl group on carbon 21 have been 
shown both in vitro and in vivo to undergo esterification 
inside lung cells and therefore take a longer period of time 
to eliminate from the body (Kelly, 2009). 
Mechanism of Action 
 The physiological effects of corticosteroids are well 
M. Einhorn is pursuing a B.S. in Biology.  
39 
 
documented, and medical practitioners administer these 
drugs because the effects are beneficial to the patients. 
Corticosteroids are sometimes referred to as a “miracle 
drug” because of the diverse pathologies that are alleviat-
ed or managed by these drugs. The precise mechanism of 
action, nevertheless, is as of yet unknown. Much research 
has been done to discover this mechanism, and varying 
hypotheses have been suggested. There is a strong possi-
bility that corticosteroids have numerous effects on a cellu-
lar level, resulting in what seems to be several valid mecha-
nisms. 
 Corticosteroids function by diffusing into a cell and 
binding to glucocorticoid receptors in the cytoplasm 
(Barnes, 2005). The receptor corticosteroid complex stimu-
lates changes in the cell by influencing transcription. Re-
search testing cardiovascular effects of the corticosteroid 
dexamethasone, found that treatment of cells with dexa-
methasone and the glucocorticoid antagonist mifepristone 
(RU 486) blocked the known effects of the corticosteroid 
(Hafezi-Moghdam et al., 2002). When cells are treated with 
mifepristone, the glucocorticoid receptor is inactivated. 
When the cell with the inactivated receptor is treated with 
corticosteroid, no corticosteroid effect takes place. This 
demonstrated that a corticosteroid must bind to the recep-
tor for an effect to occur in the cell. 
 This theory was replicated in a study showing that 
dexamethasone inhibits vasculogenesis in a tumor through 
suppressing vascular endothelial growth factor A. Treat-
ment of steroid along with mifepristone prevented this 
suppressive effect (Greenberger et al., 2010). A limit of the 
conclusion, however, is that both studies were done using 
the same corticosteroid dexamethasone, and therefore, 
does not prove that other corticosteroids need to bind to 
the glucocorticoid receptor to have an effect. 
 Further proof of this theory lies in the clinically 
seen observation that different topical corticosteroids have 
different potencies. Corticosteroids are therefore separat-
ed into classes. In the United States, corticosteroids are 
divided in classes from one, the extremely potent, to sev-
en, the least potent. In Europe, classes are numbered 
differently with class one, the mild corticosteroids, to class 
four, the strongest of the corticosteroids. Percentage of 
active ingredient in corticosteroid creams, lotions, or oint-
ments fluctuates depending on the strength of the cortico-
steroid. 
 In a double blind study testing the bioavailability of 
different corticosteroids, desoximetasone 0.25%, clobeta-
sol-17-propionate .05%, hydrocortisone 1.0%, and betame-
thasone dipropionate .064% were applied on the volar 
forearm of 30 healthy volunteers. After six hours, skin color 
changes were noted. The degree of skin blanching is asso-
ciated with the efficacy of the corticosteroid. Though the 
corticosteroid concentration in each cream was different, 
the vasoconstrictive effect of the corticosteroid, as seen by 
blanching of the skin was quite similar between three of 
the four corticosteroids tested. Hydrocortisone caused 
milder skin blanching and in fewer individuals, but is known 
to be a weak corticosteroid so the results were not atypical 
(Borelli et al., 2008). The clinical observation that three of 
the four creams caused similar blanching despite differing 
concentrations, clearly demonstrated that corticosteroids 
differ in potency. 
 Research has shown that each corticosteroid has a 
different binding affinity to the glucocorticoid receptor be-
cause of structural differences (Kelly, 2009). Clinical trials 
show that the change in binding affinity from one cortico-
steroid to another is associated with the potency of the 
corticosteroid (Kelly, 2009). This correlation that greater 
the affinity of the corticosteroid to the receptor the more 
powerful its effects, bolsters the theory that corticoster-
oids need to bind to the glucocorticoid receptor to have 
physiological effects. The corticosteroid receptor complex 
causes numerous changes in the cell, both in the short 
term as well as long term. 
 After binding to the corticosteroid, the activated 
glucocorticoid receptor complex is transported from the 
cytoplasm into the nucleus and binds to the promoter of 
specific genes containing the glucocorticoid response ele-
ments. This induces transcription of glucocorticoid re-
sponse elements mRNA (Barnes, 2005). In endothelial cells, 
dexamethasone induced promoter activity for the gluco-
corticoid response elements and caused transcription of 
these genes beginning four hours after treatment of cells. 
Actinomycin D, which inhibits transcription, and 5, 6-
dichlorobenzimidazole riboside, which inhibits RNA poly-
merase, given in conjunction with the corticosteroid 
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blocked the promoter activity (Hafezi-Moghdam et al., 
2002). These results indicate the influence of corticoster-
oids on transcription, which will subsequently affect pro-
teins produced by the cell. 
 Some of the genes contained within the glucocor-
ticoid response elements code for proteins with anti-
inflammatory effects, such as interleukin 10. Leucine zip-
per protein and I kappa beta alpha (IkBα) are proteins syn-
thesized in a cell exposed to corticosteroid. They suppress 
an important proinflammatory transcription factor called 
nuclear factor kappa B (Barnes, 2006). Some genes are 
indirectly inhibited by corticosteroids through the suppres-
sion of nuclear factor kappa B (Maneechotesuwan et al., 
2009). There are also genes directly inhibited by cortico-
steroids, and these genes are considered to be negative 
glucocorticoid response elements. Examples of these di-
rectly suppressed genes include genes that regulate oste-
ocalcin and keratin (Barnes, 2006). The suppression of 
these proteins results in common side effects of cortico-
steroids, such as epidermal, and to a lesser extent, dermal 
thinning and increased risk of fractures. 
 Corticosteroids inhibit proteins that have deleteri-
ous effects on specific pathologies. As a result corticoster-
oid therapies are beneficial for these diseases. A study 
seeking to explain the function of corticosteroid therapy in 
the treatment of infantile hemangioma found that the me-
dicinal property was due to a negative glucocorticoid re-
sponse elements and a decrease in amount of a corre-
sponding protein. Corticosteroids suppressed the expres-
sion of vascular endothelial growth factor A mRNA and 
protein in hemangioma stem cells in a dose dependent 
manner, suggesting that corticosteroids may slow the 
growth of cancer cells. . Untreated infantile hemangioma 
cells express larger quantities of vascular growth factor 
than normal endothelial cells, but use of corticosteroids 
inhibited growth factor mRNA and protein. This effect was 
replicated using different corticosteroids including dexa-
methasone, prednisone, prednisolone, methylpredniso-
lone, and hydrocortisone (Greenberger et al., 2010) lead-
ing to a conclusion that this effect is common to all cortico-
steroids. Other proangiogenic factors were suppressed in 
the hemangioma stem cells, in addition to vascular endo-
thelial growth factor A. These factors included matrix met-
alloproteinase 1, interleukin-6, and monocyte chemo-
attractant protein 1. The latter two molecules are both 
involved with the immune system (Greenberger et al., 
2010). Inhibition of metalloproteinase is also seen in corti-
costeroid treatment of arthritic diseases (Fubini et al., 
2001). Steroidal medications induce changes in gene ex-
pression. The expressed genes, as well as the repressed 
genes, have physiological effects on the cell, which are 
attributed to the corticosteroid. 
 Numerous studies demonstrate that corticoster-
oids affect transcription, but this does not explain all of the 
physiological effects of corticosteroids. Corticosteroids 
inhibit cytokine production in T helper 2 cells, specifically 
interleukin 4, 5, and 13. The genes coding these interleu-
kins are not fully regulated by nuclear factor kappa B and 
are not known to be part of the glucocorticoid response 
element (Maneechotesuwan et al., 2009). Additionally, 
effects of dexamethasone were seen in cells after only ten 
minutes , quite a short time for the transcription of gluco-
corticoid response element genes and translation of corre-
sponding proteins. Furthermore, although the inhibitor of 
transcription actinomycin D blocked the promoter of the 
glucocorticoid response elements, overall the molecule did 
not inhibit the physiological changes of a cell exposed to 
dexamethasone (Hafezi-Moghdam et al., 2002). Based on 
these observations, the theory that corticosteroids binding 
to a receptor cause a cell to express certain genes and re-
press others is insufficient. 
 T cells exposed to anti CD3 antibodies and anti CD 
28 antibodies cause GATA-3, a transcription factor, to be 
imported into the nucleus and stimulate the expression of 
interleukin 4 and 5. T lymphocytes that were exposed to 
the corticosteroid, known as fluticasone propionate, were 
found to have inhibited GATA-3, which affected interleukin 
gene expression. Interleukin 4 expression, which is regulat-
ed by GATA-3, was inhibited, and GATA-3 did not bind to 
the promoter of interleukin 5. Research on this phenome-
na found that GATA-3 uses importin alpha for protein to 
enter the nuclear membrane. Activated glucocorticoid re-
ceptors use importin alpha for nuclear translocation as 
well, leading to competition between GATA-3 and the glu-
cocorticoid receptor for importin alpha. This decreased 




less nuclear translocation, less transcription, and less trans-
lation of interleukins 4,5, and 13 (Maneechotesuwan et al., 
2009). 
 Corticosteroids were found to have non-
transcriptional effects as well. Treating endothelial cells 
with dexamethasone stimulated endothelial nitric oxide 
synthase, an enzyme that has physiological effects on the 
cells. Activating the enzyme begins with the corticosteroid 
binding to the glucocorticoid receptor. The complex stimu-
lates protein kinase B (also known as Akt) either directly or 
indirectly through the phosphoinositide 3-kinase/Akt path-
way. Protein kinase B phosphorylates endothelial nitric 
oxide synthase thereby activating this enzyme (Hafezi-
Moghdam et al., 2002). Researchers carried out this exper-
iment with only one corticosteroid, dexamethasone, and 
the cells were evaluated for the function of only one en-
zyme. This raises an important question whether a corre-
sponding mechanism applies to other corticosteroids and 
the phosphorylation and activation of other enzymes.   
General Effects of Corticosteroid Drugs 
 Based on proteins produced or inhibited, as well as 
the enzymes activated in a cell exposed to corticosteroids, 
these drugs have predictable physiological effects. One of 
the most important effects of corticosteroid drugs is the 
suppression of inflammation. This effect is so significant 
that other drugs that also have anti-inflammatory proper-
ties are separated into a class titled nonsteroidal anti-
inflammatory drugs (NSAIDs).  Healthcare practitioners 
therefore often prescribe corticosteroids in the treatment 
of pathologies involving an inflammatory reaction. Inflam-
mation is associated with the immune system, and cortico-
steroids influence cytokine production, increasing some 
cytokines while decreasing others, resulting in an immuno-
suppressant effect. Repressing the immune system is ben-
eficial for the treatment of pathologies caused by an over-
active immune system, but detrimental to a patient on 
long-term corticosteroid therapy. Immune system suppres-
sion increases patient susceptibility to infections, which 
can become quite serious. This effect is especially deleteri-
ous to patients with compromised immune system due to 
other medical issues. Corticosteroids affect mRNA tran-
scription and proteins produced in the cell. Researchers 
are studying the effects of proteins produced or repressed 
by cells exposed to corticosteroids and the physiological 
effects these proteins have on the cell. 
 
Therapeutic Usage of Corticosteroids 
 The properties listed above are what cause corti-
costeroids to have a therapeutic influence on a wide varie-
ty of diseases. One of the most common uses of cortico-
steroids is in the treatment and management of asthma 
(Eurich et. al, 2013) and other diseases characterized by an 
obstructed airway (Sibila et al, 2013). Corticosteroids are 
used to treat inflammation in other areas of the body as 
well. Therefore, corticosteroid drug therapy is commonly 
used to treat inflammatory skin disease,s such as eczema 
and psoriasis. Injections of corticosteroids are used in the 
controlling of inflammation and the suppression of matrix 
metalloproteinase activity in arthritic diseases (Fubini et 
al.,2001). Corticosteroids are beneficial for autoimmune 
disorders because of the immunosuppressive effect. Some 
pathologies, such as allergies, are aided by both the anti-
inflammatory and immunosuppressive effects of cortico-
steroids. 
 The proteins produced in cells exposed to cortico-
steroids are beneficial to some diseases. Cardiovascular 
disease can be treated using corticosteroids, though a high 
dose is needed to achieve results (Hafezi-Moghdam et al., 
2002). Dexamethasone increased the activity of the en-
zyme endothelial nitric oxide synthase (eNOS) and the pro-
duction of nitric oxide. This radical protects muscle mi-
crovessels in mice after ischemia. Under normal condi-
tions, leukocytes are present in the blood and do not ad-
here to venule walls. Following ischemia and reperfusion, 
leukocytes’ velocity in the bloodstream decreases and they 
begin to stick to the venule walls. Mice given dexame-
thasone, directly following the ischemia and reperfusion, 
did not have the decrease in leukocyte velocity and the 
increase in adhesion normally seen after ischemia and 
reperfusion (Hafezi-Moghdam et al., 2002). This effect was 
studied in the cremaster muscle, but corticosteroids were 
found to have beneficial effects on myocardium as well. 
Dexamethasone treated mice were found to have myocar-
dial infarctions affecting a smaller percentage of their re-
gion at risk for infarction, while mice in the control group 
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ty of diseases. One of the most common uses of cortico-
steroids is in the treatment and management of asthma 
(Eurich et. al, 2013) and other diseases characterized by an 
obstructed airway (Sibila et al, 2013). Corticosteroids are 
used to treat inflammation in other areas of the body as 
well. Therefore, corticosteroid drug therapy is commonly 
used to treat inflammatory skin disease,s such as eczema 
and psoriasis. Injections of corticosteroids are used in the 
controlling of inflammation and the suppression of matrix 
metalloproteinase activity in arthritic diseases (Fubini et 
al.,2001). Corticosteroids are beneficial for autoimmune 
disorders because of the immunosuppressive effect. Some 
pathologies, such as allergies, are aided by both the anti-
inflammatory and immunosuppressive effects of cortico-
steroids. 
 The proteins produced in cells exposed to cortico-
steroids are beneficial to some diseases. Cardiovascular 
disease can be treated using corticosteroids, though a high 
dose is needed to achieve results (Hafezi-Moghdam et al., 
2002). Dexamethasone increased the activity of the en-
zyme endothelial nitric oxide synthase (eNOS) and the pro-
duction of nitric oxide. This radical protects muscle mi-
crovessels in mice after ischemia. Under normal condi-
tions, leukocytes are present in the blood and do not ad-
here to venule walls. Following ischemia and reperfusion, 
leukocytes’ velocity in the bloodstream decreases and they 
begin to stick to the venule walls. Mice given dexame-
thasone, directly following the ischemia and reperfusion, 
did not have the decrease in leukocyte velocity and the 
increase in adhesion normally seen after ischemia and 
reperfusion (Hafezi-Moghdam et al., 2002). This effect was 
studied in the cremaster muscle, but corticosteroids were 
found to have beneficial effects on myocardium as well. 
Dexamethasone treated mice were found to have myocar-
dial infarctions affecting a smaller percentage of their re-
gion at risk for infarction, while mice in the control group 
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had a larger percentage of their region at risk affected by a 
myocardial infarction. Other studies have demonstrated 
that corticosteroids given to cardiovascular patients im-
proved short-term survival following a myocardial infarc-
tion. In the experiments using mice, only very high doses 
caused physiological effects, and an established clinical 
dose offered no cardiovascular protection (Hafezi-
Moghdam et al., 2002). 
 Corticosteroids are effective in reducing pain, as 
evidenced by a study comparing the effectiveness of intra-
venous hydrocortisone plus conventional treatment versus 
a placebo and conventional methods at reducing a severe 
postdural puncture headache. The results clearly showed 
the effectiveness of corticosteroids at reducing intense 
pain. Dural puncture is thought to cause a headache by 
causing cerebral spinal fluid leakage and a lessening of the 
fluid cushioning around the brain. The mechanism for the 
resolution of the headache is unknown, but possibilities 
include the anti-inflammatory properties of corticosteroids 
at the puncture site, the suppression of interleukins and 
prostaglandins, and causing the reabsorption of cerebro-
spinal fluid (Alam et al., 2012). Similarly, corticosteroids, in 
addition to antibiotics, relieved the pain and symptoms of 
patients suffering strong discomfort from pharyngitis soon-
er than than antibiotics and a placebo did (Bergeson et. al., 
2013). 
 Topical corticosteroids have the benefit of main-
taining a localized concentration of corticosteroids. Pa-
tients with bullous pemphigoid, a potentially fatal autoim-
mune disease of the skin, were divided into one group re-
ceiving treatment of 40 grams of the topical corticosteroid 
0.5% clobetasol propionate twice daily, and the other 
group was treated with one milligram per kilogram of oral 
prednisone. The topical corticosteroid was found to be 
more effective at controlling the disease and caused a low-
er incidence of side effects than the oral corticosteroid 
(Joly et al., 2002). Similarly, topical steroids were found to 
be effective at reducing inflammation and ear discharge in 
otitis media. Clinicians commonly prescribe ear drops, con-
taining a combination of an antibiotic, such as Augmentin®, 
and a corticosteroid, to treat otitis media with discharge 
(Florea et al., 2006). 
 Corticosteroids are used in oncology treatment of 
infantile hemangioma. They suppress vascular endothelial 
growth factor A, thereby inhibiting tumor vasculogenesis 
and limiting tumor growth (Greenberger et al., 2010). Ad-
ditional research is needed to determine whether this 
effect extends to other forms of cancer and can be used 
accordingly, as a part of treatment. Furthermore, the safe-
ty of corticosteroid therapy in cancer patients must be 
evaluated as well.   
Side Effects Common to Corticosteroids 
 The change in proteins produced by a cell exposed 
to corticosteroids has numerous effects on the cell, both 
positive and negative. Side effects of a corticosteroid de-
pend on the binding affinity, which is the potency of the 
given corticosteroid; the length of time for which it is tak-
en; and the method of introduction in the body. Side 
effects of topically applied corticosteroids generally affect 
the location of application. 
 Skin atrophy is a common effect of corticosteroids 
(Cobman and Wezel, 2006). In a double blind study, twenty 
healthy volunteers applied four different topical cortico-
steroids with differing potencies to their volar arm for four 
weeks. Researchers quantified skin atrophy, using optical 
coherence tomography to measure epidermal thickness, 
and using high frequency ultrasound to measure dermal 
thickness. Additionally, they used a profilometer, an instru-
ment that measures the profile of a given surface, to quan-
tify epidermal roughness. All of the volunteers experienced 
epidermal thinning, demonstrating the frequency of this 
side effect. The epidermis thickened considerably after 
treatment was completed, but three weeks after finishing 
treatment, the epidermis was still measurably thinner than 
it had been before treatment. The subjects were followed 
for only three weeks following steroid use, so the length of 
time for which this effect persisted and the time needed 
for the epidermis to return to its original thickness was not 
determined in the study. The dermis of volunteers thinned 
as well. The dermal thinning, however, was less than that 
of the epidermal thinning. Additionally, three weeks post-
treatment the dermis had almost returned to its original 
thickness. Using the profilometer, areas of corticosteroid 
use had a decreased roughness. The effect of the cortico-
steroid on the skin corresponded with its known potency; 




thinning. Hydrocortisone, a mild corticosteroid, did not 
cause significant atrophy. 
 It is evident from this study that in many cases, the 
skin, particularly the epidermis, is affected by corticoster-
oid use (Cobman and Wezel, 2006). This effect is likely be-
cause corticosteroids directly inhibit genes coding the pro-
tein keratin; these genes are part of the negative GRE. 
Healthcare providers should treat a patient using the least 
potent corticosteroid found to be effective and should 
monitor skin changes in the patient (Cobman and Wezel, 
2006). Similar results were obtained in a study testing the 
effects of corticosteroids on different skin phototypes. An 
additional side effect of corticosteroids was seen in the 
study: changed skin pigmentation (Shlivko et al., 2013). 
The method used to introduce corticosteroids into the 
body influences the side effects experienced by the pa-
tient. The effects of topical corticosteroids are concentrat-
ed and limited to the location of application. Therefore, 
topical corticosteroids may be more effective for treat-
ment of the skin and are known to have a lower toxicity as 
compared to oral corticosteroids (Joly et al., 2002). 
 Based on numerous studies, adverse effects of oral 
corticosteroids are not detected at low and infrequent dos-
es. Patients treated with oral corticosteroids were evaluat-
ed for risk of bone fractures. Those on medium to high 
doses of prednisone or prednisolone were found to have 
increased risk of fracture. Significantly, the fracture risk 
remained elevated for up to a year after the last dose, indi-
cating that effects of corticosteroids linger even after dis-
continuing drug therapy . Budesonide has a low systemic 
availability, as it is designed for release in the intestine. 
Due to the low systemic concentration, budesonide was 
not associated with increased risk of fracture. Methylpred-
nisolone is generally not used regularly, and as a result, did 
not cause an increased risk of fractures. Likewise, low dos-
es of corticosteroids and doses taken intermittently were 
not associated with increased risk (Vestergaard et al., 
2008). Similarly, short-term use of corticosteroids in 
treating the intense pain of a postdural headache did not 
cause short-term negative effects (Alam et al., 2012). Addi-
tionally, in the study using corticosteroids to treat severe 
sore throat, the corticosteroids did not exacerbate illness. 
Likewise, the use of corticosteroids in croup and mononu-
cleosis did not worsen the infection (Bergeson et al., 2013). 
These studies did not follow up with the patients to see if 
any long-term effect or non-immediate reaction to the cor-
ticosteroid occurred. Additionally, it is possible that corti-
costeroids cause subtle effects that are not detected by 
laboratory means currently available. 
 A low to medium dose of inhaled corticosteroid is 
not likely to cause adverse effects (Kelly, 2009). As an im-
munosuppressant, regular corticosteroid use may nega-
tively impact the immune system’s ability to fight infection. 
Eighty nine patients, with a diagnosis of community-
acquired pneumonia and had previously taken inhaled cor-
ticosteroids, were compared with a control group of 575 
patients, with the same diagnosis who had not taken any 
inhaled corticosteroids. Inhaled corticosteroids are used in 
the control of disorders involving lung inflammation, such 
as asthma and COPD. The corticosteroid inhaler is general-
ly used daily or on a regular basis. The patients, who had 
previously used inhaled corticosteroids, were more likely 
to have an illness caused by an antibacterial resistant mi-
crobe and presented a more critical case of pneumonia 
upon admission. Clinicians measure pneumonia by using 
the Pneumonia Severity Index and Curb-65 scores, which 
measures the likelihood of the pneumonia patient to die 
from their disease within 30 days (Sibila et al., 2013). Simi-
larly, a study of 6874 patients, who had community-
acquired pneumonia, found that inhaled corticosteroid use 
in high-risk patients increased the risk of a repeat incident 
of pneumonia by ninety percent (Eurich et al., 2013). 
Healthcare providers should relay this risk to asthmatic 
patients and instruct the patient, or the patient’s caregiver, 
to seek medical care as soon as they feel symptoms of 
pneumonia. Earlier diagnosis will lead to treatment and a 
better prognosis. 
 Treatment of arthritis using corticosteroids has 
been proven effective. There are negative effects, howev-
er, and a healthcare provider should perform a benefit ver-
sus risk assessment and treat the patient accordingly. Cor-
ticosteroid injections into joints negatively affected chon-
drocytes, in addition to the cartilage damaged by the ar-
thritis. A single dose of methylprednisolone succinate sup-
pressed the expression of type 2 procollagen mRNA and 
decreased the relative percentage of the fibronectin form 
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had a larger percentage of their region at risk affected by a 
myocardial infarction. Other studies have demonstrated 
that corticosteroids given to cardiovascular patients im-
proved short-term survival following a myocardial infarc-
tion. In the experiments using mice, only very high doses 
caused physiological effects, and an established clinical 
dose offered no cardiovascular protection (Hafezi-
Moghdam et al., 2002). 
 Corticosteroids are effective in reducing pain, as 
evidenced by a study comparing the effectiveness of intra-
venous hydrocortisone plus conventional treatment versus 
a placebo and conventional methods at reducing a severe 
postdural puncture headache. The results clearly showed 
the effectiveness of corticosteroids at reducing intense 
pain. Dural puncture is thought to cause a headache by 
causing cerebral spinal fluid leakage and a lessening of the 
fluid cushioning around the brain. The mechanism for the 
resolution of the headache is unknown, but possibilities 
include the anti-inflammatory properties of corticosteroids 
at the puncture site, the suppression of interleukins and 
prostaglandins, and causing the reabsorption of cerebro-
spinal fluid (Alam et al., 2012). Similarly, corticosteroids, in 
addition to antibiotics, relieved the pain and symptoms of 
patients suffering strong discomfort from pharyngitis soon-
er than than antibiotics and a placebo did (Bergeson et. al., 
2013). 
 Topical corticosteroids have the benefit of main-
taining a localized concentration of corticosteroids. Pa-
tients with bullous pemphigoid, a potentially fatal autoim-
mune disease of the skin, were divided into one group re-
ceiving treatment of 40 grams of the topical corticosteroid 
0.5% clobetasol propionate twice daily, and the other 
group was treated with one milligram per kilogram of oral 
prednisone. The topical corticosteroid was found to be 
more effective at controlling the disease and caused a low-
er incidence of side effects than the oral corticosteroid 
(Joly et al., 2002). Similarly, topical steroids were found to 
be effective at reducing inflammation and ear discharge in 
otitis media. Clinicians commonly prescribe ear drops, con-
taining a combination of an antibiotic, such as Augmentin®, 
and a corticosteroid, to treat otitis media with discharge 
(Florea et al., 2006). 
 Corticosteroids are used in oncology treatment of 
infantile hemangioma. They suppress vascular endothelial 
growth factor A, thereby inhibiting tumor vasculogenesis 
and limiting tumor growth (Greenberger et al., 2010). Ad-
ditional research is needed to determine whether this 
effect extends to other forms of cancer and can be used 
accordingly, as a part of treatment. Furthermore, the safe-
ty of corticosteroid therapy in cancer patients must be 
evaluated as well.   
Side Effects Common to Corticosteroids 
 The change in proteins produced by a cell exposed 
to corticosteroids has numerous effects on the cell, both 
positive and negative. Side effects of a corticosteroid de-
pend on the binding affinity, which is the potency of the 
given corticosteroid; the length of time for which it is tak-
en; and the method of introduction in the body. Side 
effects of topically applied corticosteroids generally affect 
the location of application. 
 Skin atrophy is a common effect of corticosteroids 
(Cobman and Wezel, 2006). In a double blind study, twenty 
healthy volunteers applied four different topical cortico-
steroids with differing potencies to their volar arm for four 
weeks. Researchers quantified skin atrophy, using optical 
coherence tomography to measure epidermal thickness, 
and using high frequency ultrasound to measure dermal 
thickness. Additionally, they used a profilometer, an instru-
ment that measures the profile of a given surface, to quan-
tify epidermal roughness. All of the volunteers experienced 
epidermal thinning, demonstrating the frequency of this 
side effect. The epidermis thickened considerably after 
treatment was completed, but three weeks after finishing 
treatment, the epidermis was still measurably thinner than 
it had been before treatment. The subjects were followed 
for only three weeks following steroid use, so the length of 
time for which this effect persisted and the time needed 
for the epidermis to return to its original thickness was not 
determined in the study. The dermis of volunteers thinned 
as well. The dermal thinning, however, was less than that 
of the epidermal thinning. Additionally, three weeks post-
treatment the dermis had almost returned to its original 
thickness. Using the profilometer, areas of corticosteroid 
use had a decreased roughness. The effect of the cortico-
steroid on the skin corresponded with its known potency; 




thinning. Hydrocortisone, a mild corticosteroid, did not 
cause significant atrophy. 
 It is evident from this study that in many cases, the 
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oid use (Cobman and Wezel, 2006). This effect is likely be-
cause corticosteroids directly inhibit genes coding the pro-
tein keratin; these genes are part of the negative GRE. 
Healthcare providers should treat a patient using the least 
potent corticosteroid found to be effective and should 
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2006). Similar results were obtained in a study testing the 
effects of corticosteroids on different skin phototypes. An 
additional side effect of corticosteroids was seen in the 
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The method used to introduce corticosteroids into the 
body influences the side effects experienced by the pa-
tient. The effects of topical corticosteroids are concentrat-
ed and limited to the location of application. Therefore, 
topical corticosteroids may be more effective for treat-
ment of the skin and are known to have a lower toxicity as 
compared to oral corticosteroids (Joly et al., 2002). 
 Based on numerous studies, adverse effects of oral 
corticosteroids are not detected at low and infrequent dos-
es. Patients treated with oral corticosteroids were evaluat-
ed for risk of bone fractures. Those on medium to high 
doses of prednisone or prednisolone were found to have 
increased risk of fracture. Significantly, the fracture risk 
remained elevated for up to a year after the last dose, indi-
cating that effects of corticosteroids linger even after dis-
continuing drug therapy . Budesonide has a low systemic 
availability, as it is designed for release in the intestine. 
Due to the low systemic concentration, budesonide was 
not associated with increased risk of fracture. Methylpred-
nisolone is generally not used regularly, and as a result, did 
not cause an increased risk of fractures. Likewise, low dos-
es of corticosteroids and doses taken intermittently were 
not associated with increased risk (Vestergaard et al., 
2008). Similarly, short-term use of corticosteroids in 
treating the intense pain of a postdural headache did not 
cause short-term negative effects (Alam et al., 2012). Addi-
tionally, in the study using corticosteroids to treat severe 
sore throat, the corticosteroids did not exacerbate illness. 
Likewise, the use of corticosteroids in croup and mononu-
cleosis did not worsen the infection (Bergeson et al., 2013). 
These studies did not follow up with the patients to see if 
any long-term effect or non-immediate reaction to the cor-
ticosteroid occurred. Additionally, it is possible that corti-
costeroids cause subtle effects that are not detected by 
laboratory means currently available. 
 A low to medium dose of inhaled corticosteroid is 
not likely to cause adverse effects (Kelly, 2009). As an im-
munosuppressant, regular corticosteroid use may nega-
tively impact the immune system’s ability to fight infection. 
Eighty nine patients, with a diagnosis of community-
acquired pneumonia and had previously taken inhaled cor-
ticosteroids, were compared with a control group of 575 
patients, with the same diagnosis who had not taken any 
inhaled corticosteroids. Inhaled corticosteroids are used in 
the control of disorders involving lung inflammation, such 
as asthma and COPD. The corticosteroid inhaler is general-
ly used daily or on a regular basis. The patients, who had 
previously used inhaled corticosteroids, were more likely 
to have an illness caused by an antibacterial resistant mi-
crobe and presented a more critical case of pneumonia 
upon admission. Clinicians measure pneumonia by using 
the Pneumonia Severity Index and Curb-65 scores, which 
measures the likelihood of the pneumonia patient to die 
from their disease within 30 days (Sibila et al., 2013). Simi-
larly, a study of 6874 patients, who had community-
acquired pneumonia, found that inhaled corticosteroid use 
in high-risk patients increased the risk of a repeat incident 
of pneumonia by ninety percent (Eurich et al., 2013). 
Healthcare providers should relay this risk to asthmatic 
patients and instruct the patient, or the patient’s caregiver, 
to seek medical care as soon as they feel symptoms of 
pneumonia. Earlier diagnosis will lead to treatment and a 
better prognosis. 
 Treatment of arthritis using corticosteroids has 
been proven effective. There are negative effects, howev-
er, and a healthcare provider should perform a benefit ver-
sus risk assessment and treat the patient accordingly. Cor-
ticosteroid injections into joints negatively affected chon-
drocytes, in addition to the cartilage damaged by the ar-
thritis. A single dose of methylprednisolone succinate sup-
pressed the expression of type 2 procollagen mRNA and 
decreased the relative percentage of the fibronectin form 
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unique to cartilage. Researchers found that injecting the 
recommended dose of methylprednisolone acetate into 
synovial fluid resulted in a high corticosteroid concentra-
tion, that was maintained for a longer period of time, be-
cause the half-life of corticosteroid in synovial fluid is 
found to be 10.3 hours (Fubini et al., 2001). 
Conclusion 
 Corticosteroids are a class of drugs with similarities 
in structure, and they have immunosuppressant and anti-
inflammatory properties with comparable mechanisms. 
Gene expression is affected by corticosteroids, with genes 
coding the glucocorticoid response elements expressed 
more than normal, while other genes coding interleukins 
are inhibited. Various corticosteroids are used in a wide 
variety of disparate pathologies, because of their  
immunosuppressant and anti-inflammatory properties. 
These properties are responsible for the side effects of cor-
ticosteroids, including a decreased immune function and 
changes in cells exposed to high concentrations of  
corticosteroids. Differences in corticosteroid structure in-
fluence bioavailability and affinity to glucocorticoid recep-
tor; both of which are directly related to potency.  
Additionally, the method of introduction of corticosteroid 
into the body, as well as the place of introduction, are ma-
jor determinants of corticosteroid effects. 
 Overall, corticosteroids are an important method 
of treatment for illnesses involving an overactive immune 
system and/or inflammation. However, their use should be 
limited, as much as possible, due to their side effects. Be-
fore prescribing corticosteroids, physicians and other 
healthcare providers should evaluate the patient’s overall 
immune function and assess the need for corticosteroid 
therapy. Healthcare providers should experiment with the 
patient to determine the least potent, lowest dose of corti-
costeroid found to be effective, particularly in patients re-
quiring long-term use. Patients or the primary caregiver, in 
the case of children or the elderly, need to be informed of 
the possible side effects such as increased risk of infection 
and thinning of the skin. Awareness of corticosteroid risk, 
along with monitoring by medical professionals, will likely 
diminish many of the adverse side effects accompanying 
corticosteroid use. 
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